Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Pinker, Katja; Riedl, Christopher C.; Weber, Wolfgang

doi:10.1007/s00259-017-3687-3

Cited by 127 publications

(112 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumors are known to upregulate GLUT transporters in a noninsulin-dependent manner (15), with subsequent similarities to that seen in brain tissues in which glucose is an obligate substrate (1,16). Given that TLG had a reservoir or sink effect in the brain FDG uptake, it is possible that a similar effect could occur in the primary tumor and/or its metastasis, given the similar mechanism of noninsulin-dependent GLUT that these methods provide better correlation to outcomes than do anatomic criteria such as Response Evaluation Criteria in Solid Tumors (13).…”

Section: Discussionmentioning

confidence: 99%

Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria

Viglianti¹,

Wale²,

Wong³

et al. 2018

Radiology

View full text Add to dashboard Cite

Purpose To examine the effect metabolic burden (tumor and/or cardiac myocyte uptake) has on fluorine 18 fluorodeoxyglucose (FDG) distribution in organs and tissues of interest. Materials and Methods Positron emission tomographic (PET)/computed tomographic (CT) scans at the Ann Arbor Veterans Affairs hospital from January to July 2015 were reviewed. A total of 107 scans (50 patients; mean age, 64.3 years ± 13.2 [standard deviation]) had metabolic tissue burden assessed by using total lesion glycolysis (TLG) obtained from autosegmentation of the tumor and/or cardiac tissue. Standardized uptake value (SUV) and subsequent normalized SUV uptake in target organs and tissues were compared with 436 FDG PET/CT scans previously reported in 229 patients as a function of TLG to describe the effect(s) that metabolic burden has on reference tissue (blood pool, liver, and brain) FDG uptake. Subsequent regression by using linear mixed-effects models was used. If the slope of the regression was significantly (P < .05) different than zero, then an effect from TLG was present. Results There was a negative inverse relationship (P < .0001) between FDG uptake within reference tissues (blood pool, liver, and brain) and TLG in comparison to the study population at similar blood glucose levels. This TLG effect was no longer statistically significant (P > .05) when FDG uptake was normalized to a reference tissue (eg, blood pool or liver). Conclusion Metabolic tissue burden can have a significant effect on SUV measurements for PET imaging. This effect can be mitigated by normalizing FDG uptake to a reference tissue. RSNA, 2018.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria

Viglianti¹,

Wale²,

Wong³

et al. 2018

Radiology

View full text Add to dashboard Cite

show abstract

“…PET imaging with various tracers, including 18 F-FDG, is increasingly used for evaluation of biologic response to cancer treatment (1). Reliable and repeatable quantitative PET images are therefore important for follow-up examinations.…”

mentioning

confidence: 99%

Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer

et al. 2017

View full text Add to dashboard Cite

Quantitative PET/MRI is dependent on reliable and reproducible MR-based attenuation correction (MR-AC). In this study, we evaluated the quality of current vendor-provided thoracic MR-AC maps and further investigated the reproducibility of their impact on F-FDG PET quantification in patients with non-small cell lung cancer. Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thoracic PET/MRI scan-rescan examinations within 22 d. F-FDG PET data were acquired along with 2 Dixon MR-AC maps for each examination. Two PET images (PET and PET) were reconstructed using identical PET emission data but with MR-AC from these intrasubject repeated attenuation maps. In total, 90 MR-AC maps were evaluated visually for quality and the occurrence of categorized artifacts by 2 PET/MRI-experienced physicians. Each tumor was outlined by a volume of interest (40% isocontour of maximum) on PET, which was then projected onto the corresponding PET SUV and SUV were assessed from the PET images. Within-examination coefficients of variation and Bland-Altman analyses were conducted for the assessment of SUV variations between PET and PET Image artifacts were observed in 86% of the MR-AC maps, and 30% of the MR-AC maps were subjectively expected to affect the tumor SUV. SUV and SUV resulted in coefficients of variation of 5.6% and 6.6%, respectively, and scan-rescan SUV variations were within ±20% in 95% of the cases. Substantial SUV variations were seen mainly for scan-rescan examinations affected by respiratory motion. Artifacts occur frequently in standard thoracic MR-AC maps, affecting the reproducibility of PET/MRI. These, in combination with other well-known sources of error associated with PET/MRI examinations, lead to inconsistent SUV measurements in serial studies, which may affect the reliability of therapy response assessment. A thorough visual inspection of the thoracic MR-AC map and Dixon images from which it is derived remains crucial for the detection of MR-AC artifacts that may influence the reliability of SUV.

show abstract

“…Die PET-Bildgebung ist in den diagnostischen Algorithmus vieler onkologischer Erkrankungen integriert und wird nach standardisierten Kriterien ausgewertet [33]. Darüber hinaus ist die PET/CT als Kombination aus anatomisch-morphologischer Information der CT und der In der Diagnostik von NET hat sich die in der Onkologie etablierte 18 F-2-Fluor-2-desoxy-D-Glukose( 18 F-FDG)-PET nicht als Standard durchgesetzt.…”

Section: Pet-bildgebungunclassified

State-of-the-Art-Bildgebung von neuroendokrinen Tumoren

Putzer

Gabriel

Bale

et al. 2020

J. Klin. Endokrinol. Stoffw.

View full text Add to dashboard Cite

ZusammenfassungDie PET/CT hat als Hybridbildgebung die Vorteile einer exakten Darstellung anatomisch-morphologischer Verhältnisse in der CT und einer effektiven Lokalisierung von Tumorherden in der PET unter Verwendung von Somatostatin(SST)-Analoga vereint. Die Weiterentwicklung radioaktiv markierter Derivate synthetisch hergestellter SST-Analoga und die technische Verbesserung der PET-Technik, mit höherer Auflösung bei gleichzeitig spezifischer Bindung der Radiopharmaka an verschiedene Somatostatin-Rezeptor-Subtypen hat zur Entwicklung von neuen Anwendungen in der Diagnose von neuroendokrinen Tumoren (NET) beigetragen.

show abstract

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Cited by 127 publications

References 73 publications

Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria

Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria

Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer

State-of-the-Art-Bildgebung von neuroendokrinen Tumoren

Contact Info

Product

Resources

About